10-QPeriod: Q2 FY2016

BeOne Medicines Ltd. Quarterly Report for Q2 Ended Jun 30, 2016

Filed August 10, 2016For Securities:ONCBEIGF

Summary

BeOne Medicines Ltd. (ONC) reported on August 10, 2016, for the period ending June 30, 2016. As a newly public company, BeOne Medicines is focused on establishing robust internal controls and financial reporting processes, which are described as time-consuming and costly. The company is also actively evaluating potential acquisitions and strategic partnerships, which could increase capital requirements and shareholder dilution. Significant risks and uncertainties are highlighted, including potential non-compliance with anti-bribery laws like the FCPA, which could harm the company's reputation and lead to penalties. Furthermore, the company faces risks associated with environmental, health, and safety regulations, as well as potential disruptions from cyber security breaches and broader business interruptions like natural disasters. The company's manufacturing facility in Suzhou, PRC, is under development and expected completion by 2017, with potential delays and cost overruns being a concern. Global economic downturns and the implications of Brexit are also identified as potential risks. The company has limited insurance coverage, particularly for environmental liability and toxic tort claims.

Financial Highlights

43 data points
Beta

Revenue

$393K

Net Income

-$24.12M

-6138.4% Net Margin

EPS (Diluted)

$-0.06

Total Assets

$251.23M

Cash & Equivalents

$58.08M

Free Cash Flow

-$24.71M

Financial Statements
Beta
Revenue$393K
R&D Expenses$21.12M
Operating Expenses$25.02M
Operating Income-$24.63M
Interest Expense$141K
Net Income-$24.12M
EPS (Basic)$-0.06
Shares Outstanding (Basic)427.75M

Key Highlights

  • 1BeOne Medicines is in the process of establishing internal controls over financial reporting as a newly public company, a process expected to be costly and time-consuming.
  • 2The company is actively exploring acquisitions and strategic partnerships, which carry risks such as increased capital requirements and potential shareholder dilution.
  • 3Significant legal and regulatory risks are present, including potential non-compliance with anti-bribery laws (FCPA) and environmental, health, and safety regulations.
  • 4The company faces operational risks from potential cybersecurity breaches and business disruptions due to natural disasters or other unforeseen events.
  • 5A new manufacturing facility in Suzhou, PRC, is under construction, with completion anticipated by 2017, but potential delays and cost overruns are a risk.
  • 6Global economic conditions, including Brexit, are identified as potential risks to the company's business and financial condition.
  • 7BeOne Medicines has limited insurance coverage, particularly for environmental liability and toxic tort claims, increasing potential financial exposure.

Frequently Asked Questions

As a newly public company, BeOne Medicines is focused on establishing and maintaining effective disclosure and financial controls and improving corporate governance practices. This includes hiring additional qualified accounting and financial personnel, which is described as a potentially difficult and costly process that could divert management resources from product development.

The company faces significant risks related to operating in China, including navigating a highly regulated pharmaceutical industry with potentially changing regulations, uncertainties in the interpretation and enforcement of PRC laws, and potential adverse effects from changes in PRC government economic and political policies. Additionally, there are risks associated with currency exchange restrictions and potential PRC tax liabilities if the company is deemed a 'resident enterprise'.

The company is evaluating potential acquisitions and strategic partnerships, which could increase capital requirements, dilute existing shareholders, lead to incurred debt or contingent liabilities, and divert management's attention from existing product development. The successful integration of acquired operations and intellectual property also presents challenges.

BeOne Medicines is developing a new manufacturing facility in Suzhou, PRC, expected to be completed by 2017. Risks include delays in construction and regulatory approvals, potential cost overruns, challenges in scaling up production to meet demand, and the possibility of production interruptions due to equipment failure, natural disasters, or other business disruptions. Failure to comply with current Good Manufacturing Practices (cGMP) could lead to significant delays or sanctions.